摘要
目的通过对比研究,观察骨质疏松性椎体压缩骨折的患者在经皮椎体成形术后应用唑来膦酸的临床治疗效果。方法2010年7月至2013年2月,将中山市中医院骨一科240例椎体压缩性骨折行PVP手术治疗的患者随机分成两组,治疗组在术后3日予以静滴唑来膦酸针;对照组单纯予以椎体成形术。两组患者自入院起均予以口服碳酸钙/维生素D3片,600 mg/d。分别于术前1周及术后1月、3月、6月、9月、一年行腰椎骨密度、血清PINP及β-CTX浓度检查,并进行统计分析。结果随访1年,两组患者共240例获得随访,治疗后治疗组患者在VAS评分、腰椎骨密度、血清PINP及β-CTX浓度等的变化与对照组相比均具有显著性差异,且治疗组患者的依从性较好,新发椎体骨折少。结论唑来膦酸治疗骨质疏松性椎体压缩骨折可增加患者椎体骨密度、改善患者疼痛、预防新发椎体骨折、提高患者生活质量,可用于骨质疏松性椎体压缩骨折患者PVP术后的巩固治疗。
Objective To observe the efficacy of zoledronic acid in the treatment of osteoporotic vertebral compression fracture （ OVCF） after percutaneous vertebroplasty （ PVP） .Methods Two hundred and forty OVCF patients treated with PVP from July 2010 to Feberary 2013 were randomly divided into 2 groups.The patients in the treatment group received intravenous 5 mg zoledronic acid once a year after 3 days of the operation.The patients in the control group received PVP only.The patients in both groups received oral vitamin D3 and caltrate daily.The VAS scores, BMD of the lumbar spine, PINP, and β-CTX were tested before and 1-, 3-, 6-, 9-, and 12-month after the operation.All the results were analyzed statistically.Results All the 240 patients in both groups were followed up for 1 year.Compared to those in the control group, the VAS scores, BMD of lumbar spine, PINP, andβ-CTX were significantly different to those in the control group.The patients in the treatment group had a better compliance and lower rate of new fractures of the vertebral body.Conclusion Zoledronic acid administration once a year can increase BMD, ruduce the pain and fracture risk, and improve the quality of life in OVCF patients.Zoledronic acid treatment should be used for OVCF patients after PVP operation.
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2014年第12期1428-1431,共4页
Chinese Journal of Osteoporosis
关键词
唑来膦酸
骨质疏松性椎体压缩骨折
经皮椎体成形术
Zoledronic acid
Osteoporotic vertebral compression fracture
Percutaneous vertebroplasty
